outperform price
organ execut confid set stage
fairli tale start good start well good
end think mdt print would perfect analog
headlin organ beat solid om expans
continu sustain stock momentum mind organ
rev came bp segment come in-line
continu posit commentari pipelin make us
believ organ trajectori come well
possibl provid upsid guidanc
organ tavr acceler micra pacer continu gain
share spine continu grow market live demo
surgic robot sept make us believ top-line
acceler thesi intact given back
confid margin execut commit
convers would expect mdt price-to-earnings multipl discount
vs group normal rais pt
equat price-to-earnings tweak
ep estim
diabet came buysid expec in-line guid
investor skeptic
om also came w/ ep guid rais
soft tissu robot unveil sept showcas
live demonstr system
gm miss like due product mix
tax rate remain hw anticip impact
albeit off-set benefit debt offer
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
ep rais
diabet reiter lower end
mitg rais
cvg rais
adjust tax maintain
organ revenu growth similar first quarter
rtg similar last
cvg similar last
reiter organ revenue growth acceler cours year north
impli revenu
fx rate hold expect ive impact rev
fx hw rate hold
expect om expans modest improv increas improv
msd growth first quarter
custom demand show similar strength ou upon launch us last year
cgm growth high
mazor sale continu robust w/ strong pull-through
drill product come on-line next could drive sale growth robot
final regul yet optim time
look improv rate
tax hw off-set debt offer fx also
product launch
linq accuraci blue tooth
launch non-injunct label toward end year
rtg seri product neuromod w/ sens
soft tissu robot reveal ad
fx impact gm om
gm impact product list seen expans gm sg
fx hw reflect gm
still break-out
vector studi full result
dcb panel led gain appear share
submit data impact deep studi patient follow year
intend use cash tuck-in look return earn power growth potenti
new galaxi platform new gener rcd
pfa evicd go pivot studi year
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin august
analyst jon bristow vijay kumar primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
